Diabetes Management Tech for Type II patients: Interview with Jeffrey Brewer, CEO of Bigfoot Biomedical

December 1, 2022

Bigfoot Biomedical, a medtech company based in California, has developed the Bigfoot Unity System, a diabetes management technology for patients on multiple daily injection therapy. The system uses continuous glucose monitoring data and doctor recommendations to provide insulin dose recommendations, helping patients to avoid uncertainty.

Medtech Insight


Bigfoot Looks To Unlock More Effective Treatments For Type II Diabetics

October 26, 2022

Bigfoot Biomedical’s Unity system pairs continuous glucose monitoring with smart insulin pen caps, giving patients recommendations on insulin dosing. Because patient interaction is involved, Bigfoot Biomedical can deliver insulin pump-like results to pump-ineligible type II diabetics.

Diabetes Daily


Cool New Diabetes Products We Saw at #ADA2022

June 22, 2022

We spent last week at 82nd Scientific Sessions, presented by the American Diabetes Association, one of the world’s most important diabetes conferences. It is a grand gathering of the sharpest global minds in the field. It’s also an opportunity for businesses to strut their stuff and impress the many doctors and healthcare professionals.

Here are some of the coolest new products that I saw at the #ADA2022 conference:

MMM Online


Bigfoot Biomedical taps diabetes marketing vet to lead commercialization

May 26, 2022

Bigfoot Biomedical has appointed Matt Rainville as chief commercial officer, the diabetes management company said Thursday. 
Drug Delivery


Diabetes tech is off to a hot start in 2022 - Drug Delivery Business

March 16, 2022

Diabetes tech developers have high hopes for the year ahead, some of which have already come to fruition, including Bigfoot Unity with its smart pen cap technology and holistic approach.

Drug Delivery


How Bigfoot Biomedical plans to take diabetes management forward

January 27, 2022

An interview with Bigfoot Biomedical CEO Jeffrey Brewer who, for close to 20 years, has focused on finding ways to support insulin delivery and manage diabetes.



Bigfoot Hires Three, Primes Expansion

December 16, 2021

Bigfoot Biomedical, a company dedicated to better health outcomes for people with insulin-requiring diabetes, announced three senior hires with deep experience in the diabetes and health care sectors. Matthew Clemente joins Bigfoot as senior vice president of development; Robin A. Beadle joins as vice president of marketing; and Scott Snead joins as vice president of national accounts. All three positions are new to the company as it moves to expand access to its Bigfoot Unity Diabetes Management Program.

Drug Delivery Business News


Bigfoot Biomedical Touts Cloud-based Program for Managing Diabetes

December 1, 2021

Milpitas, California-based Bigfoot designed the Bigfoot Unity platform to allow healthcare professionals (HCPs) to review patient data. The information comes from the patient’s prescribed Bigfoot Unity system, integrating with Abbott’s FreeStyle Libre 2 continuous glucose monitor (CGM).



Special Delivery: A Look at New Modes of Diabetes Care

November, 2021

New models of diabetes care could help ease the burden of both the patients and the providers, whether treatment takes place at home, in the office, or in a hospital setting.




New diabetes technology expected to improve customization, availability of real-time data

Technology advancements are allowing more comprehensive and real-time data to be available to people with diabetes and their caregivers. Devices that could most change diabetes management in the near future are connected insulin pens and caps – “a gamechanger for people with daily injections of insulin."

Mass Device


Bigfoot Biomedical diabetes management program rolls out in some U.S. states

June 24, 2021

Milpitas, Calif.-based Bigfoot’s program is now available in California, Texas, Florida, Pennsylvania, Ohio, New York, New Jersey, Massachusetts and other New England states. The program is offered as a bundle of devices, supplies and services and delivered as a 30-day subscription to eliminate upfront costs. 




Bigfoot Unity diabetes management program launched in US

June 24, 2021

Bigfoot Biomedical announced that its Bigfoot Unity diabetes management program is now available to diabetes clinics and endocrinology practices in select markets across the US.


TID Exchange


Bigfoot Unity Cleared and Ready to Step Out: Interview with Jeffrey Brewer, CEO, Bigfoot Biomedical

June 17, 2021

Bigfoot Biomedical Inc. received FDA Clearance for its Bigfoot Unity Diabetes Management System. In this interview learn more about the system and what drives Bigfoot Biomedical CEO and co-founder Jeffrey Brewer and his team.




Say Hello to the Bigfoot Unity System and Innovative Patient Training Program

June 14, 2021

Bigfoot Biomedical received FDA clearance for its Bigfoot UnityTM Diabetes Management System. The system features first-of-its-kind connected smart pen caps for all major U.S. brands of disposable insulin pens and integrates with Abbott’s FreeStyle® Libre 2 sensor.




Insulin Dosing Made Easier, Smart Pen Caps Cleared by FDA

May 17, 2021

Bigfoot Biomedical’s new diabetes management system will provide insulin dosing recommendations based on glucose data and a healthcare professional’s instructions to people with diabetes who take multiple daily injections of insulin.



Bigfoot Unity: New Connected Insulin Pen System Cleared by FDA

May 12, 2021

Bigfoot is real in the diabetes community! Yes, it’s true. An exciting new connected insulin delivery system for people with diabetes (PWDs) who prefer injections to an insulin pump has now received regulatory approval in the United States.

Fierce Biotech


Hoping to make big tracks, Bigfoot Biomedical scores FDA clearance for smart insulin pens

May 11, 2021

A smart insulin pen may not be the rarest sighting in diabetes these days, but Bigfoot Biomedical aims to stand apart with a new FDA clearance for delivery devices that provide real-time alerts for low blood sugar and instant dosing instructions.




The FDA Just Approved a Smart Insulin Pen Cap That Might Make the Life of Diabetics Easier

May 10, 2021

The Food and Drug Administration has granted approval for an innovative smart pen cap system to help those with both Type 1 and Type 2 diabetes better manage their insulin dosage. This is huge news, as the system could help diabetics eliminate the guesswork when it comes to figuring out how much insulin to take, using real-time data.


VC News Daily


Bigfoot Biomedical Secures up to $57M Debt and Equity

March 19, 2021

Bigfoot Biomedical, a company dedicated to better health outcomes for people with insulin-requiring diabetes, has secured new financing of up to $57 million from Madryn Asset Management. The company seeks to reduce the burden of living with insulin-requiring diabetes and to maximize the leverage of health care providers through data, connectivity, automation, and artificial intelligence.




Bigfoot Biomedical Secures $57M In New Funding To Support Commercialization Of Diabetes Management System

March 18, 2021

As Bigfoot awaits FDA clearance for its Bigfoot Unity System, the diabetes treatment company’s business model calls for packing the System as part of a one-stop-shop monthly subscription model. 




Digital Health 150: The Digital Health Startups Transforming The Future Of Healthcare

August 13, 2020

The Digital Health 150 is CB Insights' annual ranking of the 150 most promising digital health startups in the world. This year's winning companies include startups working on interoperability, at-home care, emerging benefits, and more.



Mass Device


Former Eli Lilly researcher joins Bigfoot Biomedical as chief medical officer

June 12, 2020 

Bigfoot Biomedical has brought on Dr. Jim Malone — a 21-year clinical research veteran at Eli Lilly & Co. — as its chief medical officer.  


MobiHealth News


Bigfoot Biomedical caps off its Series C funding at $55M, including a new $10M addition

June 3, 2020  

Pharma giant Abbott led the round with participation from Quadrant Capital Advisors Senvest Capital, Janus Henderson, Cormorant Asset Management and other funders.




Profile of a Founder: Jeffrey Brewer of Bigfoot Biomedical

May 4, 2020  

An exclusive Tech Tribune Q&A with Jeffrey Brewer, the founder and CEO of Bigfoot Biomedical, which was honored in our Best Tech Startups in Milpitas




Bigfoot’s New Connected Insulin Pen System Coming Soon

April 2020 - The promise of future diabetes technology can be uncertain, even in the best of times.

But there’s at least one exciting new connected system for people with diabetes that remains on course for launch in 2021 despite current economic woes, its makers claim.

It’s coming from Northern California–based Bigfoot Biomedical: an ambitious next-generation Automated Insulin Delivery (AID) system known as Bigfoot Unity.

Drug Delivery Business News


Abbott boosts support for Bigfoot Biomedical and its diabetes treatment tech

January 2020 - Diabetes treatment tech company Bigfoot Biomedical has raised another $45 million in the initial tranche of a Series C equity financing, with collaborator Abbott (NYSE:ABT)  as the lead investor.

Market Pathways


Bigfoot Biomedical: Solving the Puzzle of Diabetes Device Interoperability and Payor Value

September 2019 - Bigfoot Biomedical is breaking new ground in reducing the pain points in diabetes management with a simplified monthly subscription, one prescription, and one copay service model for its integrated insulin delivery platforms, to treat insulin-dependent type 1 or 2 diabetes.



Closed-loop insulin tech for diabetes will change lives

March 18, 2019 -From the outside, diabetes may look like a simple condition to manage but it's actually a constant math test where the right answer is nebulous and the stakes range as high as death. But a new technology about to get broader commercial release could make insulin management the self-driving car of endocrinology.

Medtech Dive


Bigfoot could shake up insulin delivery market, analyst says

January 22, 2019 - Bigfoot Biomedical, developer of insulin-delivery devices targeted for launch next year, is poised to become a major competitor to established companies such as Medtronic, Dexcom and Insulet, Jefferies analyst Raj Denhoy predicts in a recent research note.

The analyst estimates Bigfoot's total addressable market at $21 billion in the United States alone, an opportunity that rivals even the largest of big pharma opportunities, he said.

Minneapolis Star Tribune


In bid for diabetes market, Medtronic, among others, talking money

July 28, 2018 - In their quest to make care better for people with diabetes, medical device companies are doing lots of innovating — in prices.

Medtronic is rolling out an offer to pay up to $25,000 if patients using its most advanced insulin pump end up in the hospital. Abbott Laboratories debuted its latest continuous glucose monitor at prices designed to be low enough to foster quick worldwide adoption. Most radically, Bigfoot Biomedical plans to offer its upcoming insulin devices for a monthly subscription price instead of an upfront fee of thousands of dollars.



Bigfoot brings in $55M Series B to propel integrated diabetes platform

March 29, 2018 - This week, Bigfoot Biomedical announced a $55 million Series B to advance their push to integrate glucose monitoring, insulin delivery and smart software. The financing will support a pivotal trial and other efforts to gain premarket approval (PMA) from the FDA.

Beyond tying together monitoring and delivery, Bigfoot wants to simplify the whole process of diabetes management. Under one prescription, users could receive the infusion system (unless they choose to give their own shots), glucose monitor, the app that talks to both and various disposables – though not insulin.

Fierce Biotech


Bigfoot raises $37M to trial AI-enabled insulin delivery devices

December 19, 2017 - The series B gives Bigfoot the financial muscle to move its automated insulin infusion device into a pivotal clinical trial in the U.S. next year.

Milpitas, CA-based Bigfoot is working on two products: an insulin infusion device that mimics the function of the pancreas and a smart injection pen. Bigfoot is putting a network of sensors and algorithms around the delivery devices to automate and optimize diabetes management.



Bigfoot Biomedical Raises $37 Million for Diabetes Device

December 18, 2017 - Bigfoot Biomedical Inc., a developer of a system to manage Type 1 diabetes, has raised a $37 million venture round as it prepares to seek regulatory approval for the product next year.



Bigfoot and Abbott: A Match Made in Heaven? An Interview with Bigfoot Biomedical CEO Jeffrey Brewer

July 31, 2017 - But perhaps the most interesting (and somewhat surprising) new deal in the AP space comes from Bigfoot Biomedical, which continues to demonstrate its willingness to break new ground in pursuit of the most patient-friendly solutions for people with diabetes.

A Sweet Life


Bigfoot Biomedical Chooses Abbott’s Libre Over Dexcom’s CGM

August 1, 2017 - After two and a half years of development, during which the company has raised over $40M in funding, the company has rejected one of the most respected names in diabetes tools––Dexcom––to partner with Abbott Laboratories for its initial launch. It’s not easy to make technology changes but Brewer, the CEO of Bigfoot, felt the switch was crucial. The difference in the two products came down to calibration and accuracy.

Diabetes Mine


NEWS: Bigfoot Closed Loop to Use Next-Gen Abbott FreeStyle Libre

July 17, 2017 - “In the first generation of automated systems, we think sensors that require calibration have been the crippling aspect of the user experience. We’ve learned from our own personal experiences and from what we’ve seen in data modeling, that calibration is the biggest risk to a closed loop. People don’t do it well, or consistently or even at all. And that turns out to be a big problem. Our concern is that systems that require calibration aren’t going to be as easy to use or as safe as those that don’t require it.”

Chicago Tribune


Diabetics can avoid finger pricks with new app from Abbott, Silicon Valley partner

July 13, 2017 - When Jeffrey Brewer's son was 15, the boy nearly lost his life because he took too much insulin. The diabetic teen took insulin to eat a large bag of chips late at night. But about 20 minutes later, he forgot about that first dose and took another. He spent two days in the hospital, his father said. "It was only by a miracle that my wife woke up at 4 a.m. and checked on him," said Brewer, president and CEO of Bigfoot Biomedical. "He would have been dead by 7 a.m." Now, Bigfoot Biomedical and north suburban-based Abbott Laboratories hope to help prevent such problems — and make life easier for millions of people with diabetes — with a new partnership announced Thursday.



Jeffrey Brewer speaks at TCOYD ONE Conference: "The Artificial Pancreas"

June 24, 2017 - “Artificial pancreas, or automated insulin delivery, is a solved problem from a technology perspective. What’s really NOT solved is how to build a solution that everybody can use and that is going to get reimbursed and prescribed by doctors. This is the challenge that Bigfoot has undertaken.”




“Not Good Enough”: How One Dad Led the Change in Diabetes Devices through Grassroots Research and Collaboration

April 6, 2017 - In 2002, Bigfoot Biomedical CEO Jeffrey Brewer’s technology career was flourishing, having founded two successful startup dot-coms that later became publicly traded companies. He had just moved his family from Silicon Valley to New York City, and was ready for new challenges. But when his young son received a devastating diagnosis just weeks after the family settled into their new home, Brewer found himself unable to focus on anything else. Stunned by the lack of information, high risk of error and antiquated devices available to help manage his son’s type 1 diabetes, Brewer began laying the groundwork for his most important technology project to date: automated insulin delivery (AID).